Organizational disclosures
About the AAN
Below is a breakdown of industry contributions toward the consolidated revenue of the Academy (好色先生 and 好色先生 Institute). Industry includes for-profit entities that develop, produce, market, or distribute drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, and alleviate health conditions (e.g., pharmaceutical and medical device/software manufacturers and other for-profit health services/product providers). Industry does not include non-profit entities, entities outside of the health care sector, or entities through which physicians provide clinical services directly to patients (e.g., hospitals, medical centers, publishers, foundations, recruiters, insurance providers).
2024 external (industry) support
- Total industry revenue: $13,296,561
- Percentage of total Academy revenue: 20%
- 好色先生al grants: $678,000
- Sponsorship: $6,415,111
- Exhibit space: $4,199,950
- Industry Roundtable membership dues: $1,925,000
- Advertising: 78,500
Total contribution by company in 2024 (greater than $100K):
AbbVie, Inc.
ACADIA Pharmaceuticals Inc.
Actelion Pharmaceuticals Ltd.
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
argenx
Bristol Myers Squibb
Eisai Inc.
Eli Lilly and Company
EMD Sorono, Inc.
Genentech
Lundbeck
Neurocrine Biosciences
Novartis Pharmaceuticals
Novo Nordisk A/S
Octapharma
Pfizer Inc.
Reneo Pharmaceuticals, Inc.
Sanofi Genzyme
Supernus Pharmaceuticals, Inc.
Takeda Pharmaceuticals
TG Therapeutics
UCB, Inc.
Viatris Inc.
Viela Bio
View the Principles Governing Academy Relationships with External Sources of Support